Health

Pfizer says committed with govt to make vaccine available in India

Global pharma major Pfizer on Thursday said it remains committed to engaging with the Indian government to explore opportunities to make Pfizer/BioNTech vaccine available in the country.

The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against Covid-19 with the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA)granting a temporary authorisation for its emergency use.

“Right now we are in discussions with many governments around the world and remain committed to engaging with the Government of India and explore opportunities to make this vaccine available for use in the country,” a Pfizer spokesperson said in a statement.

Pfizer is committed to ensuring everyone has the opportunity to have access to the vaccine, and is working closely with governments, it added.

“During this pandemic phase, Pfizer will supply this vaccine only through government contracts based on agreements with respective government authorities and following regulatory authorisation or approval,” the statement said.

The UK regulator, MHRA has granted a temporary authorisation for emergency use of Covid-19 mRNA vaccine.

This constitutes the first Emergency Use Authorisation following a worldwide phase 3 trial of a vaccine to help fight the pandemic, Pfizer said on Wednesday.

“As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world,”  Pfizer Chairman and Chief Executive Officer Albert Bourla said on Wednesday.

In November, NITI Aayog member (Health) V K Paul, who also heads the National Task Force on Covid-19, had said the arrival of the Pfizer vaccine in the country might take some months.

“The arrangement of cold-chains for storing the vaccine developed by Pfizer at a low temperature of minus 70 degrees Celsius is a big challenge and it will not be easy for any nation. But then, if at all it has to be obtained, we are examining what we need to do…and will work out a strategy,” he had said.

Currently in India, Pune-based Serum Institute of India has said that it will apply for emergency use licensure for AstraZeneca-Oxford vaccine in two weeks.

Phase-3 clinical trial of the indigenously-developed vaccine candidate of Bharat Biotech and the Indian Council of Medical Research (ICMR) is also underway.

While vaccine candidate of Zydus Cadila has completed the phase-2 clinical trial, pharma major Dr Reddy’s Laboratories has started the combined phase 2 and 3 clinical trials of the Russian Covid-19 vaccine, Sputnik V, in India.

Another domestic firm Biological E Ltd has also started early phase 1 and 2 human trials of its Covid-19 vaccine candidate.

By PTI

3 Comments

3 Comments

  1. Pingback: บริษัท eBET Casino

  2. Pingback: วิเคราะห์บอลวันนี้

  3. Pingback: enjoy life vegan dark chocolate bars dairy free chocolate

Leave a Reply

Your email address will not be published.

two × five =

News is information about current events. News is provided through many different media: word of mouth, printing, postal systems, broadcasting, electronic communication, and also on the testimony of observers and witnesses to events. It is also used as a platform to manufacture opinion for the population.

Contact Info

Address:
D 601  Riddhi Sidhi CHSL
Unnant Nagar Road 2
Kamaraj Nagar, Goreagaon West
Mumbai 400062 .

Email Id: [email protected]

West Bengal

Eastern Regional Office
Indsamachar Digital Media
Siddha Gibson 1,
Gibson Lane, 1st floor, R. No. 114,
Kolkata – 700069.
West Bengal.

Office Address

251 B-Wing,First Floor,
Orchard Corporate Park, Royal Palms,
Arey Road, Goreagon East,
Mumbai – 400065.

Download Our Mobile App

IndSamachar Android App IndSamachar IOS App
To Top
WhatsApp WhatsApp us